Retatrutide, a triple agonist (GLP-1, GIP, glucagon receptor), showed roughly 24% weight loss at 48 weeks in phase 2 trials (Jastreboff 2023, NEJM )
There are other factors, like cost, availability, and side effects, which make patients seek better options
Some studies show as many as 15% of participants experiencing some form of shedding while on a GLP-1, while other research acknowledges that evidence supporting any sort of causative relationship as sparse and conflicting. Whats happening here
Deep Sedation If you have deep sedation, you will be unaware of what is going on during the procedure
It binds exclusively to the glucagon-like peptide-1 receptor, where it slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses glucagon, and acts on central appetite centers to reduce food intake